Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Until today this year the stock’s price performance recorded a decrease of -2.74%. However, over the last six months, the performance has been weaker by 20.75%. The price of DAWN decreased -14.87% over the last 30 days. And in the last five days, it has fallen by -10.07%.
Day One Biopharmaceuticals Inc had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $17.85 on 03/01/24, while the lowest price during the same period was $9.67 on 10/20/23.
52-week price history of DAWN Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Day One Biopharmaceuticals Inc’s current trading price is -20.45% away from its 52-week high, while its distance from the 52-week low is 46.85%. The stock’s price range over this timeframe has been between $9.67 and $17.85. The shares of the Healthcare sector company recorded a trading volume of approximately 1.38 million for the day, which was comparatively higher than the average daily volume of 0.61 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Day One Biopharmaceuticals Inc (DAWN) has experienced a quarterly rise of 1.28% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.24B and boasts a workforce of 155 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 14.24, with a change in price of +2.06. Similarly, Day One Biopharmaceuticals Inc recorded 602,610 in trading volume during the last 100 days, posting a change of +16.97%.
DAWN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for DAWN stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
DAWN Stock Stochastic Average
Day One Biopharmaceuticals Inc’s raw stochastic average for the past 50 days is currently at 15.41%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 19.49%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 48.86% and 59.98%, respectively.
